Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>This is a special, one-time report on Thorne HealthTech which presents itself as a captivating short-term investment prospect, particularly in light of the recent reports of its speculated sale.</li><li>Despite Thorne's stock price exhibiting volatility and relatively stagnant appreciation over the past year, its potential sale could act as a catalyst for change.</li><li>In this report, we have carried out a fundamental analysis of the historical financial statements of the company.</li></ul>

This is a special, one-time report on Thorne HealthTech which presents itself as a captivating short-term investment prospect, particularly in light of the recent reports of its speculated sale.Despite Thorne's stock price exhibiting volatility and relatively stagnant appreciation over the past year, its potential sale could act as a catalyst for change.In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

Thorne HealthTech Up For Sale: An M&A Arbitrage Opportunity? – Major Drivers

United States

Thorne HealthTech, Inc. operates as a science-driven wellness company. The Company offers actionable insights and personalized data, products, and services that help individuals take a proactive approach to improve and maintain their health over their lifetime. Thorne HealthTech serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Thorne HealthTech Inc (THRN US)

Thorne HealthTech Up For Sale: An M&A Arbitrage Opportunity? – Major Drivers

This is a special, one-time report on Thorne HealthTech which presents itself as a captivating short-term investment prospect, particularly in...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)